Last edition
News about "Dr Osamu Okuda"
Chugai Pharmaceutical Files Japan Approval for Gazyva in Idiopathic Nephrotic Syndrome
Chugai Pharmaceutical files a regulatory application in Japan for Gazyva to treat Idiopathic Nephrotic Syndrome (INS), based on phase 3 INShore study results.
Dr. Osamu Okuda | 15/05/2026 | By News Bureau
Chugai Launches Elevidys Gene Therapy for Duchenne Muscular Dystrophy in Japan
Elevidys receives conditional approval and NHI listing for ambulatory DMD patients aged three to under eight years; launch backed by Phase III EMBARK study and strengthened safety measures.
Dr Osamu Okuda | 23/02/2026 | By News Bureau | 209
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
Dr Osamu Okuda | 11/10/2025 | By Dineshwori | 603
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy